Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?

Pharmacological treatments, including finasteride and oral contraceptives, that inhibit 5α-RI, which results in a blood and brain allopregnanolone decrease also affect subunit expression of GABAA receptor and are associated with mood symptoms and suicide and are part of post-finasteride syndrome. Post-finasteride syndrome, in addition to depression, anxiety and cognitive deficits also induces sexually-related side effects, […]

Macular Abnormalities Associated With 5α-Reductase Inhibitor

Among 31 male patients with foveal cavitation, 5-ARI was used for 10 of 14 patients (71.4%) with macular abnormalities of unknown origin and for 2 of 17 patients (11.8%) with macular abnormalities of well-known specific origin… Optical coherence tomography imaging showed a disease spectrum ranging from tiny foveal cavitation to an impending macular hole. Of […]

An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors

Post-finasteride syndrome (PFS) has been described as physical, neurological, or psychiatric side effects which persist for three or more months after discontinuing the medication, affecting approximately 900,000–1.5 million men. In 2015, the National Institute of Health (NIH) added PFS to their list of genetic and rare disease… Analysis of FAERS data suggests [adverse events] of […]

Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia

While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during […]

France’s FDA Equivalent Issues Information Point and Fact Sheet on Finasteride Adverse Effects

December 19, 2019 Dear Friends: France’s FDA-equivalent agency last week issued an Information Point and fact sheet for men currently taking finasteride for hair loss, or for those considering taking the drug for hair loss. “Developed in conjunction with concerned patient associations and health professionals, this fact sheet aims to reinforce patient information on the […]